JointHealth™ express December 8, 2010
Exciting news for British Columbian patients
As of last month, the Ministry of Health Services is accepting input from patients about specific drugs under review via a new website, called Your Voice. Through this website, patients, caregivers, and patient advocacy groups can add their voices to the BC PharmaCare drug review process.
The input is reviewed by the Drug Benefit Council, which then gives recommendations on if and how a drug should be covered by PharmaCare. PharmaCare then makes a decision based on those recommendations and available resources. Policies and plans already in place also factor in the decision making process.
Currently on the Your Voice website, people can provide their feedback about tocilizumab (Actemra®). Tocilizumab is used for the treatment of adult patients with moderate to severe rheumatoid arthritis. If you are eligible, that is, you have rheumatoid arthritis (RA), or you are a caregiver to someone who has RA, or your organization represents patients with this disease, then you can provide input for consideration by the Drug Benefit Council using the online questionnaire or a printable questionnaire.
It is an opportunity for you to share your perspectives on drug decisions that affect you.
Click here to provide your feedback.
The deadline for submitting your input on this particular medication is midnight on December 29, 2010.
Arthritis Consumer Experts
www.jointhealth.org
Exciting news for British Columbian patients
As of last month, the Ministry of Health Services is accepting input from patients about specific drugs under review via a new website, called Your Voice. Through this website, patients, caregivers, and patient advocacy groups can add their voices to the BC PharmaCare drug review process.
The input is reviewed by the Drug Benefit Council, which then gives recommendations on if and how a drug should be covered by PharmaCare. PharmaCare then makes a decision based on those recommendations and available resources. Policies and plans already in place also factor in the decision making process.
Currently on the Your Voice website, people can provide their feedback about tocilizumab (Actemra®). Tocilizumab is used for the treatment of adult patients with moderate to severe rheumatoid arthritis. If you are eligible, that is, you have rheumatoid arthritis (RA), or you are a caregiver to someone who has RA, or your organization represents patients with this disease, then you can provide input for consideration by the Drug Benefit Council using the online questionnaire or a printable questionnaire.
It is an opportunity for you to share your perspectives on drug decisions that affect you.
Click here to provide your feedback.
The deadline for submitting your input on this particular medication is midnight on December 29, 2010.
Arthritis Consumer Experts
www.jointhealth.org
Arthritis Consumer Experts
ACE thanks Arthritis Research Canada (ARC) for its scientific review of ACE and JointHealth™ information and education programs.